DK2327764T3 - Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer - Google Patents

Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer

Info

Publication number
DK2327764T3
DK2327764T3 DK09075536.4T DK09075536T DK2327764T3 DK 2327764 T3 DK2327764 T3 DK 2327764T3 DK 09075536 T DK09075536 T DK 09075536T DK 2327764 T3 DK2327764 T3 DK 2327764T3
Authority
DK
Denmark
Prior art keywords
cancer
disease virus
preparation
newcastle disease
medical treatment
Prior art date
Application number
DK09075536.4T
Other languages
Danish (da)
English (en)
Inventor
Christine M Csatary
Laszlo K Csatary
Original Assignee
United Cancer Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United Cancer Res Inst filed Critical United Cancer Res Inst
Application granted granted Critical
Publication of DK2327764T3 publication Critical patent/DK2327764T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
DK09075536.4T 2009-11-30 2009-11-30 Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer DK2327764T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09075536A EP2327764B1 (en) 2009-11-30 2009-11-30 New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer

Publications (1)

Publication Number Publication Date
DK2327764T3 true DK2327764T3 (da) 2012-04-02

Family

ID=41581942

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09075536.4T DK2327764T3 (da) 2009-11-30 2009-11-30 Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer

Country Status (11)

Country Link
US (2) US8377450B2 (https=)
EP (2) EP2327764B1 (https=)
JP (1) JP5807788B2 (https=)
KR (1) KR20120106741A (https=)
CN (1) CN102803477B (https=)
AT (1) ATE539148T1 (https=)
CA (1) CA2782189C (https=)
DK (1) DK2327764T3 (https=)
ES (1) ES2380289T3 (https=)
IL (1) IL207623A (https=)
WO (1) WO2011064630A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2380289T3 (es) * 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
KR101653401B1 (ko) * 2013-08-28 2016-09-12 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄ
KR101636683B1 (ko) * 2013-08-28 2016-07-07 주식회사 바이오포아 내열성이 향상된 뉴캣슬병 바이러스 ｂｐ ａｃｎｄｍ
EP3215520B1 (en) * 2014-11-07 2022-01-05 Case Western Reserve University Cancer immunotherapy using virus particles
RU2644676C1 (ru) * 2016-10-18 2018-02-13 Общество с ограниченной ответственностью "Витагор" (ООО "ВИТАГОР") Штамм вируса болезни Ньюкасла NDVH-2 для изучения возможности разработки на его основе вирусного онколитического препарата
KR101964610B1 (ko) * 2017-03-13 2019-04-03 대한민국 신규한 종양용해성 바이러스 및 이의 용도
EP3552608A1 (en) * 2018-04-09 2019-10-16 Rapo Yerape B.H. Ltd Increased activity of oncoloytic newcastle disease virus
WO2020043835A1 (en) * 2018-08-31 2020-03-05 Thaller, Arno Novel recombinant newcastle disease virus
CN113913553B (zh) * 2021-10-15 2024-08-27 广西壮族自治区兽医研究所 基因ⅻ型新城疫病毒荧光定量rt-pcr检测试剂盒及其引物对

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197846B (en) 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DE3806565A1 (de) * 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
US5215745A (en) * 1988-04-27 1993-06-01 United Cancer Research Institute Method for treating viral diseases with attenuated virus
HU203983B (en) 1988-12-05 1991-11-28 Mta Allatorvostudomanyi Kutato Process for producing living vaccine against fowlpox
AU673827B2 (en) 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
US5602023A (en) * 1992-03-24 1997-02-11 Csatary; Laszlo K. Pharmaceutical product containing live, stabilized virus for the therapy of viral and malignant diseases and process for preparing the same
FR2701580B1 (fr) 1993-02-10 1995-03-24 Bull Sa Procédé d'administration d'applications avec des protocoles standards.
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
JPH08116976A (ja) 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst 免疫用核酸調製物およびこれを用いた免疫方法
DK0770397T3 (da) 1995-10-18 2004-08-09 Akzo Nobel Nv Newcastle disease viruskombinationsvaccine
FR2750866B1 (fr) 1996-06-27 1998-11-27 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur le virus de la laryngotracheite infectieuse aviaire
CN101618049A (zh) 1997-10-09 2010-01-06 威尔斯塔特生物公司 使用病毒来治疗赘生物
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
US7244558B1 (en) 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
AU4606000A (en) 1999-06-10 2001-01-02 Agricultural Research Council Vaccine for newcastle disease virus
CA2414396A1 (en) 2000-06-26 2002-01-03 The United States Of America, As Represented By The Secretary Of Agricul Ture Production of vaccines using transgenic plants
CA2412493C (en) 2000-06-26 2010-11-09 Wellstat Biologics Corporation Purging of cells using viruses
ES2278810T3 (es) 2000-11-02 2007-08-16 Intervet International Bv Nucleoproteina recombinante mutante del virus de la enfermedad de newcastle (ndv) como marcador de vacuna.
IL145397A0 (en) 2001-09-12 2002-06-30 Yissum Res Dev Co Compositions and methods for treatment of cancer
WO2005113013A2 (en) 2004-05-20 2005-12-01 Theravir Management L.P. Compositions of ndv and methods of use thereof for treatment of cancer
US20050220818A1 (en) 2002-06-21 2005-10-06 Wellstat Biologics Corporation Administration of therapeutic viruses
ES2388537T3 (es) * 2002-08-23 2012-10-16 Merck Sharp & Dohme Corp. Inhalador dosificador que contiene una formulación en suspensión de aerosol
CA2502890A1 (en) 2002-11-05 2004-05-27 Wellstat Biologics Corporation Treating carcinoid neoplasms with therapeutic viruses
WO2005013920A2 (en) 2003-03-24 2005-02-17 Wellstat Biologics Corporation Newcastle disease virus administration
CA2519337A1 (en) 2003-03-24 2005-03-03 Wellstat Biologics Corporation Anti-cancer virus desensitization method
US20060018836A1 (en) 2003-11-25 2006-01-26 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain having a p53 independent oncolytic effect
WO2005051433A1 (en) 2003-11-25 2005-06-09 United Cancer Research Institute Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
US20070207149A1 (en) 2004-04-27 2007-09-06 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
CN1772886A (zh) 2005-09-02 2006-05-17 中国农业科学院哈尔滨兽医研究所 表达传染性法氏囊病毒VP2基因的重组新城疫LaSota弱毒疫苗株
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
KR100801180B1 (ko) 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
WO2008065053A1 (en) 2006-11-27 2008-06-05 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Multi-modal cancer therapy using viral hitch-hiking
US20100178684A1 (en) * 2006-12-21 2010-07-15 Woo Savio L C Transgenic oncolytic viruses and uses thereof
CN101205544B (zh) * 2007-08-07 2010-12-08 中国人民解放军第四军医大学 肿瘤靶向性重组新城疫病毒及其构建方法
ES2380289T3 (es) * 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer

Also Published As

Publication number Publication date
ES2380289T3 (es) 2012-05-10
HK1175495A1 (en) 2013-07-05
JP2013511975A (ja) 2013-04-11
EP2327764A1 (en) 2011-06-01
KR20120106741A (ko) 2012-09-26
US20140030229A1 (en) 2014-01-30
US20110129446A1 (en) 2011-06-02
JP5807788B2 (ja) 2015-11-10
WO2011064630A1 (en) 2011-06-03
CN102803477B (zh) 2014-12-10
EP2507366A1 (en) 2012-10-10
ATE539148T1 (de) 2012-01-15
IL207623A0 (en) 2011-03-31
CA2782189C (en) 2018-07-10
US8377450B2 (en) 2013-02-19
EP2327764B1 (en) 2011-12-28
WO2011064630A8 (en) 2012-05-24
CA2782189A1 (en) 2011-06-03
CN102803477A (zh) 2012-11-28
IL207623A (en) 2014-04-30

Similar Documents

Publication Publication Date Title
DK2327764T3 (da) Ny klon af Newcastle disease-virus, dens fremstilling og dens anvendelse ved medicinsk behandling af cancer
FIC20240036I1 (fi) Geeniterapia, joka ilmentää ihmisen hyytymistekijä IX:n muunnosta R338L
EP2249861A4 (en) Treating neurodegenerative diseases with progranulin (pgrn)
DK2276485T3 (da) Anvendelse af epothilon d i behandling af tau-associerede sygdomme,herunder alzheimers sygdom
UA102065C2 (xx) Заміщені 4-арил-1,4-дигідро-1,6-нафтиридинаміди і їх застосування$замещенные 4-арил-1,4-дигидро-1,6-нафтиридинамиды и их применение
CY2017019I2 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
BRPI1013394A2 (pt) "composto, composição farmacêutica, uso do composto, e, método para tratar um paciente infectado com virus da hepatite c."
IL217540A (en) Oral composition for use in oral disinfection or in treating an oral disease
WO2012038068A8 (en) Means and methods for the prediction of treatment response of a cancer patient
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
EP2278999C0 (en) EAR PREPARATIONS FOR THE TREATMENT OF EAR DISEASES AND CONDITIONS
DK1673104T3 (da) Fremføring af terapeutiske forbindelser til hjernen og andre væv
HUS1500058I1 (hu) Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
DK2262778T3 (da) 1-benzyl-3-hydroxymethylindazolderivativer og brug deraf i behandling af sygdomme baseret på ekspression af mcp-1, cxcr1 og p40
EA201171186A1 (ru) Сокристалл этравирина и никотинамида
IL216967B (en) The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases
IL219579B (en) Use of fusion proteins for preparation of medicaments for treatment and prophylaxis of diseases of the respiratory tract
DK1670482T4 (da) Anvendelse af ciclesonid til behandlingen af respiratoriske sygdomme
SI1940409T1 (sl) Nove zdravilske kombinacije za zdravljenje bolezni dihalnih poti
DK1962869T3 (da) Behandling af luftvejssygdomme
DK1594500T3 (da) Behandling af bakterielle sygdomme i respirations-organerne ved lokal applikation af fluorkinoloner
NZ599521A (en) Use of 4-[ethyl(dimethyl)ammonio]butanoate in the treatment of cardiovascular disease
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
EA201390925A1 (ru) Производные санглиферина и способы их получения